Straits Times Index
3,323.93 +9.79 (+0.30%) Nikkei
39,131.39 +326.74 (+0.84%) Hang Seng
18,138.00 +110.29 (+0.61%) FTSE 100
8,281.55 +43.83 (+0.53%) Bitcoin USD
60,994.85 -1,296.07 (-2.08%) CMC Crypto 200
1,272.85 -36.87 (-2.81%)
RMD Dec 2024 165.000 put
- Yahoo Finance
How Lilly is joining Novo in the crusade to circumvent Medicare's block on weight loss drugs
The leaders in the business of weight-loss drugs, Novo Nordisk and Eli Lilly, are fighting on a number of fronts to get Medicare officials to pay for the popular medicines.
- Yahoo Finance Video
Eli Lilly seeks to expand Zepbound use to treat sleep apnea
Eli Lilly (LLY) is reporting success in the use of Zepbound — one of the pharmaceutical giant's landmark GLP-1 weight-loss drugs — to treat sleep apnea. Yahoo Finance Health Reporter Anjalee Khemlani joins The Morning Brief to discuss Eli Lilly's filing for approval from the US Food and Drug Administration (FDA) for this use case and how it may affect makers of CPAP (Continuous Positive Airway Pressure) sleep devices, such as Philips (PHG) and ResMed (RMD). For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
- Barrons.com
It's Not Just a Bad Day for Chip Stocks. ResMed Is the S&P 500’s Top Decliner.
ResMed stock was the worst performer in the S&P 500 Monday as Eli Lilly’s weight-loss medicine showed signs of reducing sleep apnea. Lilly said its medication tirzepatide, sold under the brand names Mounjaro and Zepbound, reduced obstructive sleep apnea severity by up to 62.8%. ResMed sells CPAP machines that treat sleep apnea, so this news was not a good sign for investors.
